BGI Genomics Co., Ltd. (SHE:300676)

Market Cap	18.18B
Revenue (ttm)	4.03B
Net Income (ttm)	-101.62M
Shares Out	381.35M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	0.10 (0.21%)
Ex-Dividend Date	Jul 4, 2024

Volume	4,212,487
Average Volume	5,207,130
Open	48.62
Previous Close	47.63
Day's Range	47.45 - 49.20
52-Week Range	33.33 - 70.30
Beta	0.97
RSI	36.65
Earnings Date	Apr 26, 2025

About BGI Genomics

BGI Genomics Co., Ltd. provides genomic sequencing and proteomic services in China and internationally. The company offers solutions to various applications, such as basic research covering human, plant, animal, and microbial species; clinical research in human health; genetic testing and screening; drug discovery and development; and agriculture and biodiversity preservation and sustainability. It provides DNA, RNA, and customized sequencing solutions; and mass spec services, as well as COVID-19 PCR test kits and COVID lab solutions. In additi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1999
• Employees: 3,752
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300676

Financial Performance

In 2023, BGI Genomics's revenue was 4.35 billion, a decrease of -38.33% compared to the previous year's 7.05 billion. Earnings were 92.90 million, a decrease of -88.43%.